From Rationale to Results: Tyrosine Kinase Inhibitors in Systemic Mastocytosis

In "From Rationale to Results: Tyrosine Kinase Inhibitors in Systemic Mastocytosis," the expert pharmacists examined the following critical questions:

What was the clinical rationale for investigating the tyrosine kinase pathway in systemic mastocytosis?

What is the clinical data to support the use of tyrosine kinase inhibitors in indolent systemic mastocytosis?

Since advanced systemic mastocytosis is often associated with other malignancies, how can overall survival be improved in these patients?

Led by the moderator, the panelists discussed the rationale for targeting the KIT D816V mutation with tyrosine kinase inhibitors and reviewed six-month and three-year PIONEER trial data showing sustained reductions in symptom burden and improved quality of life with avapritinib in indolent systemic mastocytosis, with minimal treatment discontinuation due to adverse events. They also addressed strategies for improving overall survival in advanced disease complicated by secondary hematologic malignancies, emphasizing early hematology involvement, risk stratification, and achieving molecular response.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, "Treating Advanced Systemic Mastocytosis: Current Options and Emerging Therapies," further explores systemic mastocytosis, highlighting treatment selection between midostaurin and avapritinib, supporting clinical trial data, and emerging investigational agents including next-generation KIT inhibitors, monoclonal antibodies, and CAR T-cell therapy.